Journal Article

Characteristics and Management of Patients with Alopecia Areata and Selected Comorbid Conditions: Results from a Survey in Five European Countries

Piraccini, Bianca Maria, Marwaha, Simran, Bewley, Anthony, Vañó-Galván, Sergio, Reed, Catherine, Egeberg, Alexander, Johansson, Erin, Durand, Frederick

2024

Overview

Introduction Alopecia areata (AA) is an autoimmune condition that causes non-scarring hair loss and can impose a high psychosocial burden on patients. The presence of comorbid conditions may impact the management of AA in clinical practice. This analysis aims to describe disease characteristics and management of AA in patients with concomitant atopic, autoimmune, and psychiatric comorbid conditions. Methods Data were collected from the Adelphi Disease Specific Programme™, a cross-sectional survey of physicians and their adult patients with AA conducted in France, Germany, Italy, Spain, and the UK between October 2021 and June 2022. Patients’ disease severity was based on physician’s definition. Physician-reported data on demographics, AA clinical characteristics, comorbid conditions, and information related to AA therapies were analyzed. Analyses were descriptive. Results Overall, 239 dermatologists provided data for 2083 patients, of which 558 patients (27%) had at least one atopic, autoimmune, or psychiatric comorbid conditions. The most common comorbid conditions were atopic dermatitis, autoimmune thyroid disease, and anxiety. The mean (standard deviation) patient age for the three comorbidity groups was 37.6 years (12.1) and 56% of the patients were women ( n  = 313). In the three comorbidity groups, 51%, 50%, and 55% of patients with atopic, autoimmune, and psychiatric comorbidities had severe AA with disease progression reported as worsening in 30%, 28%, and 30%, respectively, whereas in the group with no comorbidities, 37% were described as having severe AA and 21% getting worse. Scalp hair loss was the primary sign reported across the three groups of comorbid conditions (atopic, 91%; autoimmune, 91%; psychiatric, 88%). Patients with preselected comorbidities presented more frequently AA-related signs and symptoms beyond scalp hair loss than patients without comorbid conditions. These patients were also more likely to receive topical calcineurin inhibitors, topical immunotherapy, conventional systemic immunosuppressants, and oral Janus kinase inhibitors for the treatment of their AA. Conclusion This analysis provided insights into the burden and management of AA in patients presenting with atopic, autoimmune, and psychiatric comorbid conditions in five European countries.

• Publisher: Springer Healthcare,Springer,Springer Nature B.V,Adis, Springer Healthcare
• Subject: Alopecia / Alopecia areata / Angioedema / Anxiety / Asthma / Attention deficit hyperactivity disorder / Baldness / Bipolar disorder / Brief Report / Care and treatment / Celiac disease / Clinical medicine / Comorbid conditions / Comorbidity / Complications and side effects / Connective tissue diseases / Data collection / Demographics / Dermatology / Diabetes / Diagnosis / Disease management / Hair loss / Hay fever / Inflammatory bowel disease / Insomnia / Internal Medicine / Medicine / Medicine & Public Health / Mental disorders / Oral and Maxillofacial Surgery / Patients / Physicians / Plastic Surgery / Quality of Life Research / Rheumatoid arthritis / Rhinitis / Risk factors / Urticaria